



#### **Happy Summer!**

In this bulletin, we'll share a link to our 2022 Annual Report—hot off the presses—along with information about a new provider for our voluntary Site of Care infusion program, COVID-19 coverage changes, and our spring Wellbeing Grants for local Maine organizations, along with medication and radiology updates.

#### 2022 Annual Report: Another Year Measured by Care

Looking back over 2022, Community Health Options is proud to celebrate many positive results for our Members and we're delighted to share highlights of the year. Read our 2022 Annual Report.

#### Community Health Options Expands Site of Care with Local Infusion

Community Health Options has expanded its outpatient infusion Site of Care program through a preferred provider partnership with Local Infusion—giving Members in Central Maine a new option for affordable infusion therapy, the company announced today.

<u>Local Infusion</u> recently opened in Augusta—its first infusion center in Maine—and will soon open a center in South Portland. Local Infusion also has locations in Concord and Bedford, N. H. Nurse practitioners provide all care at the centers, which offer private suites, a dedicated infusion guide to assist patients with scheduling and financial guidance, flexible hours including nights and weekends, and convenient parking.

Local Infusion is the newest addition to Community Health Options' voluntary Site of Care Incentive Program, which gives Members access to preferred infusion providers at a fraction of the cost of non-preferred providers, yielding savings of as much as 50%. Along with reducing out-of-pocket costs, the program pays Members incentives of up to \$1,000 a year to use the program.

The Community Health Options' Utilization Management Team tries to reach Members within two business days of a pre-authorization approval for infusion therapy to help them determine the best site of care—perhaps even in their home—based on the Member's location and medication being prescribed. For information, please call (855) 624-6463. Read the full news release.

## Community Health Options Coverage Ending for OTC COVID-19 Home Test Kits

With the end of the COVID-19 public health emergency, Community Health Options is no longer covering over-the-counter COVID-19 home tests. However, we will reimburse kits purchased through June 20, 2023, and will continue to cover COVID-19 vaccinations, boosters and tests when administered by in-network providers and pharmacies.

Additionally, anti-viral prescription medications used to treat COVID-19 will remain free until federal supplies are exhausted. Thereafter, treatments will be subject to cost sharing in accordance with the Member's benefit plan.

In addition, vaccines and testing from out-of-network providers will be subject to cost sharing except when those services are unavailable without delay from in-network providers.

### Maine Nonprofits Receive Wellbeing Grants

Eleven small Maine nonprofits have received more than \$50,000 in funding through Community Health Options' Wellbeing Grants to support projects that promote physical and mental health across the State of Maine, the company announced today.

"We're privileged to play a small part in these initiatives," said Kevin Lewis, president and CEO of Health Options. "From helping to buy Fat Tire bikes for an outdoor program to supporting cancer patients and addressing substance abuse disorder, it's incredible to see the life-changing work Mainers do for their neighbors."

Read the news release.

## **Resources for Cultural and Diversity Awareness**

It is important that every Community Health Options' Member has equal access to services that provide an opportunity to be healthy and well. "Think Cultural Health," provided by the U.S. Department of Health and Human Services, offers healthcare professional free resources and educational opportunities to learn about culturally and linguistically appropriate services that best serve clients with diverse backgrounds. Go to the site to learn more.

#### Policy Update: Telehealth/Telemedicine Medical Services

Effective for services on and after October 1, 2023, covered medical telehealth/telemedicine services will be reimbursed at 80% of the fee schedule allowable amount. This does not apply to behavioral health providers. You can <u>find the policy here</u>.

### We're Hiring!

We're looking for the following:

- Staff Accountant, responsibilities preparing accurate and timely monthly financial statements, including journal entries, cash management, accounts payable and receivable, and account analysis and reconciliation.
- Content Strategist, Marketing, Communications and Product, responsible for developing, executing and maintaining an impactful content strategy for Community Health Options website and stakeholder portals.
- Business System Analyst, responsible for balancing extensive familiarity with business practices
  and goals with technical aptitude to ensure that IT products and services meet these
  requirements

If you know someone who'd be great for these roles, or others listed on our website, please share the job descriptions on <u>our career page</u> or have them contact us at (207) 402-3353.

#### Medical Benefit Management Update

#### Newly Added Medications Requiring Prior Approval Through Medical Benefit

Medications that are subject to voluntary Site of Care transition are denoted with an asterisk (\*).

BRAND NAME	Generic Name
ADSTILADRIN	nadofaragene firadenovec-vncg
BRIUMVI	ublituximab-xiiy

IDACIO	adalimumab-aacf	
IXINITY	coagulation factor ix (recombinant)	
LUNSUMIO	mosunetuzumab-axgb	
PANZYGA	immune globulin, non-lyophilized	
REBYOTA	fecal microbiota	
SUNLENCA	lenacapavir	
SYFOVRE	pegcetacoplan	
XENOVIEW	xenon xe-129 hyperpolarized gas	

## **Medications Removed from Prior Approval Requirement**

BRAND NAME	Generic Name
ABRAXANE	paclitaxel
BELRAPZO	bendamustine
BENDEKA	bendamustine
TAXOL	paclitaxel
TREANDA	bendamustine

## **Medications Removed from Exclusion**

BRAND NAME	Generic Name
KLOXXADO	naloxone

## Pharmacy Benefit Management Updates (reminder; previously published)

## **Excluded Medication Additions, Effective July 1, 2023**

Drug Class	Excluded Medications	Preferred Alternatives
Cataplexy Treatment	XYREM	SODIUM OXYBATE, XYWAV
Central Nervous System Stimulants	METHYLPHENIDATEA ER 45 MG & 63 MG *, METHYLPHENIDATE ER 72 MG, RELEXXI ER 45 MG & 63 MG*, RELEXXI ER 72 MG	dexmethylphenidate er, dextroamphetamine sulfate er, dextroamphetamine-amphetamine er, methylphenidate cd, methylphenidate er, methylphenidate la, DYANAVEL XR, MYDAYIS, QUILLICHEW ER, QUILLIVANT XR, VYVANSE
Metabolic Agents	RAVICTI	sodium phenylbutyrate, PHEBURANE
Ophthalmic Agents – Vascular Endothelial Growth Inhibitors	LUCENTIS	BYOOVIZ, CIMERLI
Pulmonary Anti-Inflammatory Inhalers	ALVESCO, ARMONAIR DIGIHALER*, FLOVENT DISKUS~, FLOVENT HFA~,	ARNUITY ELLIPTA, ASMANEX HFA, ASMANEX TWISTHALER,

FLUTICASONE PROPIONATE HFA*,	QVAR REDIHALER
PULMICORT FLEXHALER*	

<sup>\*</sup> Current 2023 exclusion

# Multi-Source Brand Exclusions, Effective July 1, 2023

BRAND NAME	Generic Name
APTENSIO XR	GILENYA

<sup>~</sup> Exclusion impacts new starts only.